The Use of immunotherapy to treat Classical Hodgins Lymphoma
DOI:
https://doi.org/10.58445/rars.1571Keywords:
Cancer Immunotherapy, biologyAbstract
This research paper goes into what is classical hodgins lymphoma and the aspect of how it works and then digs into the immunotherapies related with this disease and how they work as well. It then dwells into the future aspects and the ongoing clincal trials to help make effienct treatments for CHL.
References
Chenson, B. D., & Barttlet, N. L. (2020, October 1). Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Pubmed. Retrieved June 5, 2024, from https://pubmed.ncbi.nlm.nih.gov/33010817/
Randall, M. P., & Spinner, M. A. (2023, September 11). Optimizing Treatment for Relapsed/Refractory
Classic Hodgkin Lymphoma in the Era of Immunotherapy. Pubmed. Retrieved June 15, 2024, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526852/
Cooper, M. R., & Almalki, B. (2017, June 25). Nivolumab for the Treatment of Classical Hodgkin
Lymphoma. Pubmed. Retrieved June 7, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5998472/
Stages of Hodgkin lymphoma. (n.d.). Cancer Research UK. https://www.cancer.org/cancer/types/
hodgkin-lymphoma/treating/monoclonal-antibodies.html
Ansell, S. M. (2017, April 7). Nivolumab in the Treatment of Hodgkin Lymphoma. Aacr Journals.
Retrieved June 5, 2024, from https://aacrjournals.org/clincancerres/article/23/7/1623/80686/
Nivolumab-in-the-Treatment-of-Hodgkin
Haemetol, E. J. (2016, May 30). Pembrolizumab in classical Hodgkin's lymphoma. Pubmed. Retrieved
June 5, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987237/
Armand, P., & Ansell, S. M. (2018, March 27). ivolumab for Relapsed/Refractory Classic Hodgkin
Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of
the Multicohort Single-Arm Phase II CheckMate 205 Trial. Asco Pubs. Retrieved june 4, 2024,
Downloads
Posted
Categories
License
Copyright (c) 2024 Karan Naidu, Ashley Pearson
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.